News|Articles|March 24, 2023

Curia and Corning Collaborate to Advance Biopharmaceutical Continuous-Flow Development

Author(s)Alivia Leon

Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.

Curia announced on March 23, 2023 that it is collaborating with Corning to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally. The collaboration marks the first global installation of Corning’s G1 production system to support higher-quality API-chemical production using flow-chemistry technology.

Continuous flow chemistry is crucial for the development and manufacture of pharmaceutical intermediates and APIs and provides advantages compared with traditional batch processing. It can deliver a faster and more robust material production with a higher selectivity of desired products, according to a company press release. The collaboration will combine Curia’s expertise and global network of facilities with Corning’s continuous flow technology to help drive business efficacies as well as improve patients’ lives.

“Innovation in drug development and production calls for safety at high speed,” said Christopher Conway, president, R&D, Curia, in the release. “The implementation of Corning’s G1 Production Reactor at our Albany facility expands our capability to provide scalable solutions that address complex development and manufacturing requirements facing the pharmaceutical industry. Using advanced technology and standardized workflows, Curia offers continuous flow chemistry from targeted development to commercial scale globally.”

Source: Curia


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.